These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
94 related items for PubMed ID: 20013078
1. Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer. Miki Y. Breast Cancer; 2010 Apr; 17(2):97-102. PubMed ID: 20013078 [Abstract] [Full Text] [Related]
3. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand? Jensen EH, McLoughlin JM, Yeatman TJ. Curr Opin Oncol; 2006 Jul; 18(4):374-80. PubMed ID: 16721134 [Abstract] [Full Text] [Related]
4. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer. Chow LW. Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025 [Abstract] [Full Text] [Related]
5. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Correa Geyer F, Reis-Filho JS. Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611 [Abstract] [Full Text] [Related]
6. Personalized systemic treatment for breast cancer patients: is it a reality? Shimizu C, Fujiwara Y. Breast Cancer; 2008 Aug; 15(2):141-4. PubMed ID: 18274835 [Abstract] [Full Text] [Related]
7. Mixture classification model based on clinical markers for breast cancer prognosis. Zeng T, Liu J. Artif Intell Med; 2010 Aug; 48(2-3):129-37. PubMed ID: 20005686 [Abstract] [Full Text] [Related]
8. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249 [Abstract] [Full Text] [Related]
9. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management. Malinowski DP. Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734 [Abstract] [Full Text] [Related]
10. Pharmacogenomics in breast cancer: current trends and future directions. Wajapeyee N, Somasundaram K. Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432 [Abstract] [Full Text] [Related]
11. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM. Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897 [Abstract] [Full Text] [Related]
17. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Kaklamani V. Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367 [Abstract] [Full Text] [Related]
18. Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers. Tan SH, Lee SC. Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):283-306. PubMed ID: 20163320 [Abstract] [Full Text] [Related]
19. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). Kim R, Tanabe K, Uchida Y, Osaki A, Toge T. Oncol Rep; 2002 Mar; 9(1):3-9. PubMed ID: 11748447 [Abstract] [Full Text] [Related]